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signiﬁcant for COL. CONCLUSIONS: Detailed costing of such
procedures provide useful estimates of health resource use which
can be applied in economic evaluations of CRC screening.
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In Mexico, breast cancer is the second most frequent cancer in
oncology patients so high quality healthcare services and an efﬁ-
cient resource use is a priority. Currently, Mexican costs of dif-
ferent oncology treatments are general and incomplete.
OBJECTIVES: To estimate in detail multiple breast cancer treat-
ments costs in two oncology hospitals in the Mexican Institute
of Social Security in Mexico City. METHODS: A case type
model was constructed to identify resource use with the aid of
expert opinion in radiotherapy, surgical, and chemotherapy ser-
vices in two high speciality oncology hospitals (“Centro Médico
Nacional La Raza” and “Centro Médico Nacional Siglo XXI”),
during the last six-months of 2005. The total costs of each treat-
ment was established with the case-mix technique and the
research perspective was that of the health care payer’s. Direct
costs include: drugs, health staff wages, instrumental and
medical equipment, laboratory and gabinet exams, and other
resources for medical services. Indirect costs include: energy,
water, gas, infraestructure, administrative costs, and others sig-
niﬁcant overheads. RESULTS: The costs estimation for surgery
procedures were: Lumpectomy US$1075 and Mastectomy
US$3291.80. In radiotherapy services tangential ﬁelds (TF) had
a mean cost per intervention of US$849.90 and a breast com-
plete cycle (BCC) was estimated in US$1284.10. Chemotherapy
treatments showed different mean costs: CMF (6 cycles)
US$624.90; FEC (4 cycles) US$1682.50; FEC (6–8 cycles)
US$2847.30; Navelbine (6 cycles) US$3583.80, CarboGem (6
cycles) US$5374.70; Capacitabine (6 cycles) US$6279.60; 
Epirubicina + Taxotere (4 cycles) US$11,607.30, and
Trastuzumab US$16,572. CONCLUSIONS: Total costs of treat-
ment per patient with breast cancer was estimated in Mexico
(one surgical, radiotherapy and chemotherapy procedure was
always included). The cheapeast treatment scenario included:
lumpectomy, TF and CMF with a cost of US$2264.20 and the
highest cost scenario was found using rebuilding surgery, BCC
and Trastuzumab with a cost of US$20,477.10.
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OBJECTIVES: Three-dimensional conformal radiotherapy and
intensity-modulated radiotherapy permit more accurate con-
forming of treatment beams to the shape of target organs; other
sources of geometric variations, such as patient movement, posi-
tioning uncertainties, and organ motion, can result in complica-
tions due to irradiation of normal tissues. This assessment
evaluated the evidence on the Calypso® 4D Localization System
(“System”). This is a real-time three-dimensional target tracking
system that was developed to aid in tumor target localization
during radiation therapy. It utilizes implanted wireless transpon-
ders that respond to an AC activation wave with a low-energy
radio-frequency return signal that can be used to obtain real-time
positional information of the target organ. METHODS: The
MEDLINE® database and Cochrane Library were searched for
all articles published during the period commencing January
1995 through October 2005 using subject headings and terms.
A total of nine abstracts reporting limited data on the mecha-
nism and accuracy of the System were presented at the 2004 and
2005 annual meetings of the ASTRO. Comparators included
electronic portal imaging devices (EPID); CT, including standard
CT and CT-on-rails; ultrasound, including B-mode Acquisition
and Targeting (BAT®); and X-ray, including the CyberKnife®.
RESULTS: Initial clinical results indicated eleven of 20 evaluable
patients were localized and tracked with the System; compared
to standard radiographic x-rays, localization and tracking by the
System demonstrated a mean 3D difference of 1.5mm (SD 0.9).
Two of 11 (18%) patients exhibited signiﬁcant organ motion
exceeding 5mm over an eight-minute tracking period with the
excursions persisting over one minute. Preliminary data were
available for ﬁve patients (193 fractions) from a second cohort
which conﬁrmed early ﬁndings. PROM also indicated patient
preference for the System. CONCLUSION: 4D tracking and
localization improves target organ irradiation in comparison to
existing technologies because by improved detection of organ
motion in real time.
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OBJECTIVE: The issue of efﬁciency in providing treatment is a
critical in the current environment of escalating cost of medical
care and rising number of uninsured and underinsured. Improv-
ing efﬁciency would give a room for charity and uncompensated
care for the indigent population. To describe any variation in the
efﬁciency of proﬁt and non-proﬁt Cancer Centers. These centers
usually are associated with a national or local hospital chain,
Policy implications due to these variations would be in form of
the level of service and access for the community and indigent
populations. METHODS: Unit of analysis: Cancer Centers (CC).
Cross-sectional study for the year, 1995 Dependent variables:
Full-time Equivalent Employee Regression analysis and descrip-
tive statistics will be used in this study. RESULTS: For-Proﬁt
Cancer Center showed more cost cutting and efﬁcient way to
operate than Non-Proﬁt centers. The most efﬁcient centers were
located in the Western region of the country followed by North-
east, the Midwestern and region and the southern region of
United States. Cancer centers with average number of beds equal
or below 50 beds were the most efﬁcient in terms of minimizing
cost. This indicates that Cancer centers suffer from diseconomy
of scale. CONCLUSIONS: The importance of the study stems
from the debate over the effect of the healthcare cost on access
to healthcare. If efﬁciency is not used to improve the cost of treat-
ment, and the services provided by the Cancer Center, then
society might be better off by having a single payer system to
pressure for more efﬁciency and less disparity in the healthcare
system. This study must be taken with a grain of salt due it lim-
itations and shortcoming.
